CD40 and Miyoshi myopathy: HCD122 (CHIR12.12) (Novartis), a novel, fully human, IgG1 antagonistic mAb specifically blocked CD40L-induced adhesion, cytokine secretion, and survival of MM, as well as induced marked ADCC against CD40+ MM cells [21].